AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 230 filers reported holding AMICUS THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.77 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,520 | +48.6% | 125,014 | +35.5% | 0.02% | +41.7% |
| Q1 2023 | $1,023 | +547.5% | 92,256 | +612.4% | 0.01% | +500.0% |
| Q4 2022 | $158 | -100.0% | 12,950 | -78.6% | 0.00% | -75.0% |
| Q3 2022 | $631,000 | +12.5% | 60,447 | +15.8% | 0.01% | +33.3% |
| Q2 2022 | $561,000 | -59.1% | 52,218 | -63.9% | 0.01% | -40.0% |
| Q1 2022 | $1,371,000 | -46.9% | 144,786 | -35.2% | 0.01% | -28.6% |
| Q4 2021 | $2,580,000 | -32.9% | 223,387 | -44.5% | 0.01% | -22.2% |
| Q3 2021 | $3,847,000 | +747.4% | 402,806 | +755.0% | 0.02% | +800.0% |
| Q2 2021 | $454,000 | -69.5% | 47,111 | -68.7% | 0.00% | -75.0% |
| Q1 2021 | $1,489,000 | -63.6% | 150,677 | -15.0% | 0.01% | -63.6% |
| Q4 2020 | $4,095,000 | -29.0% | 177,349 | -53.6% | 0.02% | -54.2% |
| Q2 2020 | $5,767,000 | +657.8% | 382,443 | +364.1% | 0.05% | +585.7% |
| Q1 2020 | $761,000 | +443.6% | 82,403 | +472.6% | 0.01% | +600.0% |
| Q4 2019 | $140,000 | -90.5% | 14,391 | -92.2% | 0.00% | -91.7% |
| Q3 2019 | $1,479,000 | +632.2% | 184,429 | +1142.4% | 0.01% | +500.0% |
| Q1 2019 | $202,000 | +25.5% | 14,845 | +44.0% | 0.00% | +100.0% |
| Q2 2018 | $161,000 | -27.1% | 10,308 | -29.7% | 0.00% | -50.0% |
| Q1 2018 | $221,000 | -35.2% | 14,662 | -38.2% | 0.00% | -33.3% |
| Q4 2017 | $341,000 | +107.9% | 23,713 | +117.8% | 0.00% | +200.0% |
| Q3 2017 | $164,000 | +7.9% | 10,888 | -28.0% | 0.00% | 0.0% |
| Q2 2017 | $152,000 | -5.0% | 15,117 | -32.5% | 0.00% | 0.0% |
| Q1 2017 | $160,000 | -44.8% | 22,398 | -61.7% | 0.00% | -50.0% |
| Q4 2016 | $290,000 | +92.1% | 58,433 | +186.5% | 0.00% | 0.0% |
| Q3 2016 | $151,000 | +15.3% | 20,395 | +31.4% | 0.00% | +100.0% |
| Q1 2016 | $131,000 | -38.2% | 15,519 | +2.5% | 0.00% | 0.0% |
| Q3 2015 | $212,000 | +103.8% | 15,146 | +21.3% | 0.00% | 0.0% |
| Q4 2014 | $104,000 | +300.0% | 12,485 | +13.6% | 0.00% | – |
| Q2 2013 | $26,000 | – | 10,986 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |